Trial Profile
A Randomised, Open-label, Three-part, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 29 Mar 2022 Status changed from active, no longer recruiting to completed.
- 30 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.
- 07 Jan 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.